Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 15;15(6):1777.
doi: 10.3390/cancers15061777.

Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment

Israel Manzanedo  1   2 , Fernando Pereira  1 , Estíbalitz Pérez-Viejo  1 , Ángel Serrano  1
Affiliations
Review

Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment

Israel Manzanedo et al. Cancers (Basel). .

Abstract

Gastric cancer (GC) has a poor prognostic and only one in four patients will have survived by 5 years after diagnosis. These poor results are due to the fact that most patients are diagnosed in advanced stages; peritoneal metastases (PM) are especially frequent and are difficult to treat. Currently, PM are considered a terminal stage of GC with a poor survival rate and are treated with palliative systemic chemotherapy. Since the beginning of the century, the treatment of PM from different origins has evolved; cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become the treatment of choice for many malignant diseases that affect the peritoneum. CRS and HIPEC have also been used for patients with GC and PM, achieving survival results that have never been achieved when using systemic chemotherapy alone. The use of HIPEC can even prevent the development of peritoneal recurrences in patients with locally advanced GC as adjuvant therapy, can reduce the volume of peritoneal disease as neoadjuvant therapy, and can control symptoms in a palliative setting. The aim of this review is to collate the current scientific evidence regarding the treatment of PM of GC origin with surgery and intraperitoneal chemotherapy.

Keywords: HIPEC; cytoreductive surgery; gastric cancer; peritoneal metastases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Therapeutic algorithm for gastric cancer with peritoneal metastases.
See this image and copyright information in PMC

References

    1. Arnold M., Abnet C.C., Neale R.E., Vignat J., Giovannucci E.L., McGlynn K.A., Bray F. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020;159:335–349.e15. doi: 10.1053/j.gastro.2020.02.068. - DOI - PMC - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Gamboa A.C., Winer J.H. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers. 2019;11:1662. doi: 10.3390/cancers11111662. - DOI - PMC - PubMed
    1. Macrì A., Morabito F. The use of intraperitoneal chemotherapy for gastric malignancies. Expert Rev. Anticancer Ther. 2019;19:879–888. doi: 10.1080/14737140.2019.1671189. - DOI - PubMed
    1. Zhang J.F., Lv L., Zhao S., Zhou Q., Jiang C.G. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages. Ann. Surg. Oncol. 2022;29:3170–3186. doi: 10.1245/s10434-021-11316-z. - DOI - PubMed

LinkOut - more resources